Další formáty:
BibTeX
LaTeX
RIS
@article{1673750,
author = {Sehnalová, Irena and Říhová, Barbora and Němeček, Radim and Kintrová, Kateřina and Demlová, Regina},
article_location = {BUCURESTI},
article_number = {3},
doi = {http://dx.doi.org/10.31925/farmacia.2020.3.25},
keywords = {bevacizumab; cetuximab; panitumumab; colorectal cancer; cost analysis},
language = {eng},
issn = {0014-8237},
journal = {FARMACIA},
title = {THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS},
url = {http://farmaciajournal.com/wp-content/uploads/2020-03-art-25-Sehnalova_Rihova_Demlova_Cehia_572-578.pdf},
volume = {68},
year = {2020}
}
TY - JOUR
ID - 1673750
AU - Sehnalová, Irena - Říhová, Barbora - Němeček, Radim - Kintrová, Kateřina - Demlová, Regina
PY - 2020
TI - THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS
JF - FARMACIA
VL - 68
IS - 3
SP - 572-578
EP - 572-578
PB - SOC STIINTE FARMACEUTICE ROMANIA
SN - 00148237
KW - bevacizumab
KW - cetuximab
KW - panitumumab
KW - colorectal cancer
KW - cost analysis
UR - http://farmaciajournal.com/wp-content/uploads/2020-03-art-25-Sehnalova_Rihova_Demlova_Cehia_572-578.pdf
L2 - http://farmaciajournal.com/wp-content/uploads/2020-03-art-25-Sehnalova_Rihova_Demlova_Cehia_572-578.pdf
N2 - Targeted monoclonal antibodies bevacizumab, cetuximab and panitumumab are reimbursed in the Czech Republic in combination with chemotherapy or alone in metastatic colorectal cancer (mCRC). However, the high cost is a potentially limiting factor. The real-world costs and effectiveness of first line bevacizumab followed by cetuximab or panitumumab (EGFRi) were retrospectively assessed from the perspective of healthcare payer. Total 71 WT KRAS patients (56% men; median age 60.5 years) were evaluated between April 2007 and May 2017. During our follow-up period (30 months on average) 55% patients died. The mean cost to PD was EUR 32,107 and EUR 24,510 in bevacizumab and EGFRi treatment respectively with median PFS 9.7 and 5.0 months. The median overall survival was 27.2 months and the mean cost from sequential therapy initiation to death was EUR 63,682. The targeted therapy made up 77%, 86% and 76% of the costs in the first line, second line and from the initiation of sequential therapy to death respectively.
ER -
SEHNALOVÁ, Irena, Barbora ŘÍHOVÁ, Radim NĚMEČEK, Kateřina KINTROVÁ a Regina DEMLOVÁ. THE REAL-WORLD COST AND EFFECTIVENESS STUDY OF TREATING mCRC WITH BEVACIZUMAB FOLLOWED BY CETUXIMAB OR PANITUMUMAB IN WT KRAS PATIENTS. \textit{FARMACIA}. BUCURESTI: SOC STIINTE FARMACEUTICE ROMANIA, 2020, roč.~68, č.~3, s.~572-578. ISSN~0014-8237. Dostupné z: https://dx.doi.org/10.31925/farmacia.2020.3.25.
|
